Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:focusesOn |
rare diseases
|
| gptkbp:formerName |
gptkb:Sigma-Tau_Pharmaceuticals
|
| gptkbp:foundedYear |
1982
|
| gptkbp:headquartersLocation |
gptkb:Gaithersburg,_Maryland,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Leadiant Biosciences
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
chenodeoxycholic acid
cystinosis treatments |
| gptkbp:operatesIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:parentCompany |
Sigma-Tau Group
|
| gptkbp:website |
https://www.leadiant.com/
|
| gptkbp:bfsParent |
gptkb:Adagen
|
| gptkbp:bfsLayer |
8
|